Since April 2022, numerous nations in Europe, North America, and Asia, including Indonesia, have reported incidences of hepatitis infection of unknown origin among children and pregnant women. Laboratory analysis of the common viral hepatitis agents (HAV, HBV, HCV, HDV, and HEV) yielded negative results. Consequently, the term "acute non-hepA–E hepatitis" has emerged to define this illness.
Several potential reasons have been associated with the acute non hepA–E hepatitis of unknown origin and aetiology, including adenovirus infection, coronavirus disease 2019 (COVID-19), COVID-19 immunization, new infectious agents, a putative foodborne aetiology, medication and/or toxin exposure. However, the precise origin of this new hepatitis is unknown, making treatment recommendations extremely challenging.
Given the continuing COVID-19 pandemic, it is understandable that SARS-CoV-2 infection has been linked to this condition. Nonetheless, additional evidence undermines the theory that COVID-19 directly relates to the genesis of this illness. Therefore, additional research is still required to determine the cause of this condition in order to develop effective preventive measures and treatment.
The authors are encouraged to submit original articles on different aspects of severe non hepA–E hepatitis of unknown origin and aetiology ranging from its pathogenesis, immune response, host and viral factors, and treatment. Review articles that provide a comprehensive examination of the existing literature, as well as in silico research in these areas, will also be welcome.
Since April 2022, numerous nations in Europe, North America, and Asia, including Indonesia, have reported incidences of hepatitis infection of unknown origin among children and pregnant women. Laboratory analysis of the common viral hepatitis agents (HAV, HBV, HCV, HDV, and HEV) yielded negative results. Consequently, the term "acute non-hepA–E hepatitis" has emerged to define this illness.
Several potential reasons have been associated with the acute non hepA–E hepatitis of unknown origin and aetiology, including adenovirus infection, coronavirus disease 2019 (COVID-19), COVID-19 immunization, new infectious agents, a putative foodborne aetiology, medication and/or toxin exposure. However, the precise origin of this new hepatitis is unknown, making treatment recommendations extremely challenging.
Given the continuing COVID-19 pandemic, it is understandable that SARS-CoV-2 infection has been linked to this condition. Nonetheless, additional evidence undermines the theory that COVID-19 directly relates to the genesis of this illness. Therefore, additional research is still required to determine the cause of this condition in order to develop effective preventive measures and treatment.
The authors are encouraged to submit original articles on different aspects of severe non hepA–E hepatitis of unknown origin and aetiology ranging from its pathogenesis, immune response, host and viral factors, and treatment. Review articles that provide a comprehensive examination of the existing literature, as well as in silico research in these areas, will also be welcome.
